Enoxaparin: An update of its clinical use in the management of acute coronary syndromes

Drugs

Volumn 62, Issue 9, 2002, Pages 1407-1431

  Ibbotson, Tim ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acute coronary syndromes; Enoxaparin; Myocardial infarction; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Unstable angina

Indexed keywords

ABCIXIMAB; ALTEPLASE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TENECTEPLASE; TINZAPARIN;

ADULT; AGED; ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 0036076272     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262090-00017     Document Type: Review

References (44)

1. ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)
2. Current treatment and future prospects for the management of acute coronary syndromes: Consensus recommendations of the 1997 Ushuaia Conference, Tierra Del Fuego, Argentina
3. Low-molecular-weight heparins for acute coronary syndromes: An emergency medicine perspective
4. Overview of enoxaparin in the treatment of deep vein thrombosis
5. Enoxaparin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders
6. Enoxaparin: A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease
7. Enoxaparin: A review of its clinical potential in the management of coronary artery disease
8. Thrombosis and the pharmacology of antithrombotic agents
9. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
10. A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial)
11. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization
12. New data on the pharmacology of heparin and low molecular weight heparins
13. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease
14. Enoxaparin pharmacokinetics and pharmacodynamics in obese subjects
15. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
16. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study
17. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
18. Treatment benefit of enoxaparin in unstable angina/non-Q-wave myocardial infarction is maintained at one year followup in TIMI 11B
19. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET study)
20. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction
21. Low molecular weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction
22. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II)
23. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
24. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction
25. Enoxaparin and accelerated streptokinase in acute myocardial infarction (CLEXAS study)
26. Acclerated streptokinase and enoxaparine - A new thrombolytic regimen in acute myocardial infarction (the ASENOX study)
27. Evaluation of low-molecular-weight heparin in patients receiving fibrinolyric therapy for acute myocardial infarction
28. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
29. Safety and efficacy of subcutaneous enoxaparin and streptokinase in patients presenting acute myocardial infarction: Results of the AMI-SK trial
30. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study
31. Heparin and low-molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
32. Heparin-induced thrombocytopenia: Minimising the risks in the elderly patient
33. Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes
34. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome)
35. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)
36. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
37. The "superiority" of enoxaparin for treatment of acute coronary syndromes
38. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?
39. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
40. Acute coronary syndrome without ST elevation: Implementation of new guidelines
41. A European view on the North American Fifth Consensus on Antithrombotic Therapy
42. Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes
43. Antithrombotic agents in coronary artery disease